168 related articles for article (PubMed ID: 9621079)
1. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors.
Doyon L; Payant C; Brakier-Gingras L; Lamarre D
J Virol; 1998 Jul; 72(7):6146-50. PubMed ID: 9621079
[TBL] [Abstract][Full Text] [Related]
2. Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1.
Paulus C; Ludwig C; Wagner R
Virology; 2004 Dec; 330(1):271-83. PubMed ID: 15527852
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F; Martinez R; Peters S; Sudre P; Telenti A
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
[TBL] [Abstract][Full Text] [Related]
4. Structure-function analysis of the ribosomal frameshifting signal of two human immunodeficiency virus type 1 isolates with increased resistance to viral protease inhibitors.
Girnary R; King L; Robinson L; Elston R; Brierley I
J Gen Virol; 2007 Jan; 88(Pt 1):226-235. PubMed ID: 17170455
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility.
Whitehurst N; Chappey C; Petropoulos C; Parkin N; Gamarnik A
AIDS Res Hum Retroviruses; 2003 Sep; 19(9):779-84. PubMed ID: 14585208
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the frameshift stimulatory signal controlling a programmed -1 ribosomal frameshift in the human immunodeficiency virus type 1.
Dulude D; Baril M; Brakier-Gingras L
Nucleic Acids Res; 2002 Dec; 30(23):5094-102. PubMed ID: 12466532
[TBL] [Abstract][Full Text] [Related]
8. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of ribosomal frameshifting by oligonucleotides targeted to the HIV gag-pol region.
Vickers TA; Ecker DJ
Nucleic Acids Res; 1992 Aug; 20(15):3945-53. PubMed ID: 1508680
[TBL] [Abstract][Full Text] [Related]
10. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.
Peters S; Muñoz M; Yerly S; Sanchez-Merino V; Lopez-Galindez C; Perrin L; Larder B; Cmarko D; Fakan S; Meylan P; Telenti A
J Virol; 2001 Oct; 75(20):9644-53. PubMed ID: 11559796
[TBL] [Abstract][Full Text] [Related]
11. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.
Carrillo A; Stewart KD; Sham HL; Norbeck DW; Kohlbrenner WE; Leonard JM; Kempf DJ; Molla A
J Virol; 1998 Sep; 72(9):7532-41. PubMed ID: 9696850
[TBL] [Abstract][Full Text] [Related]
12. Stability of HIV Frameshift Site RNA Correlates with Frameshift Efficiency and Decreased Virus Infectivity.
Garcia-Miranda P; Becker JT; Benner BE; Blume A; Sherer NM; Butcher SE
J Virol; 2016 Aug; 90(15):6906-6917. PubMed ID: 27194769
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo.
Parkin NT; Chamorro M; Varmus HE
J Virol; 1992 Aug; 66(8):5147-51. PubMed ID: 1321294
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
[TBL] [Abstract][Full Text] [Related]
15. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
[TBL] [Abstract][Full Text] [Related]
16. The virion-associated Gag-Pol is decreased in chimeric Moloney murine leukemia viruses in which the readthrough region is replaced by the frameshift region of the human immunodeficiency virus type 1.
Gendron K; Dulude D; Lemay G; Ferbeyre G; Brakier-Gingras L
Virology; 2005 Apr; 334(2):342-52. PubMed ID: 15780884
[TBL] [Abstract][Full Text] [Related]
17. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
18. Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance.
Korniy N; Goyal A; Hoffmann M; Samatova E; Peske F; Pöhlmann S; Rodnina MV
Nucleic Acids Res; 2019 Jun; 47(10):5210-5222. PubMed ID: 30968122
[TBL] [Abstract][Full Text] [Related]
19. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.
Tamiya S; Mardy S; Kavlick MF; Yoshimura K; Mistuya H
J Virol; 2004 Nov; 78(21):12030-40. PubMed ID: 15479842
[TBL] [Abstract][Full Text] [Related]
20. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
